Historical Valuation
Evoke Pharma Inc (EVOK) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.50 is considered Undervalued compared with the five-year average of 4.85. The fair price of Evoke Pharma Inc (EVOK) is between 1760.31 to 1767.89 according to relative valuation methord. Compared to the current price of 11.00 USD , Evoke Pharma Inc is Undervalued By 99.38%.
Relative Value
Fair Zone
1760.31-1767.89
Current Price：11.00
99.38%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Evoke Pharma Inc (EVOK) has a current Price-to-Book (P/B) ratio of 0.00. Compared to its 3-year average P/B ratio of 1.82 , the current P/B ratio is approximately -100.00% higher. Relative to its 5-year average P/B ratio of 1.71, the current P/B ratio is about -100.00% higher. Evoke Pharma Inc (EVOK) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -100.99%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -84.46% , the current FCF yield is about -100.00% lower.
P/B
Median3y
1.82
Median5y
1.71
FCF Yield
Median3y
-100.99
Median5y
-84.46
Competitors Valuation Multiple
AI Analysis for EVOK
The average P/S ratio for EVOK competitors is 345.31, providing a benchmark for relative valuation. Evoke Pharma Inc Corp (EVOK.O) exhibits a P/S ratio of 0.50, which is -99.86% above the industry average. Given its robust revenue growth of 61.40%, this premium appears sustainable.
Performance Decomposition
AI Analysis for EVOK
1Y
3Y
5Y
Market capitalization of EVOK increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of EVOK in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is EVOK currently overvalued or undervalued?
Evoke Pharma Inc (EVOK) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.50 is considered Undervalued compared with the five-year average of 4.85. The fair price of Evoke Pharma Inc (EVOK) is between 1760.31 to 1767.89 according to relative valuation methord. Compared to the current price of 11.00 USD , Evoke Pharma Inc is Undervalued By 99.38% .
What is Evoke Pharma Inc (EVOK) fair value?
EVOK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Evoke Pharma Inc (EVOK) is between 1760.31 to 1767.89 according to relative valuation methord.
How does EVOK's valuation metrics compare to the industry average?
The average P/S ratio for EVOK's competitors is 345.31, providing a benchmark for relative valuation. Evoke Pharma Inc Corp (EVOK) exhibits a P/S ratio of 0.50, which is -99.86% above the industry average. Given its robust revenue growth of 61.40%, this premium appears sustainable.
What is the current P/B ratio for Evoke Pharma Inc (EVOK) as of Jan 09 2026?
As of Jan 09 2026, Evoke Pharma Inc (EVOK) has a P/B ratio of 0.00. This indicates that the market values EVOK at 0.00 times its book value.
What is the current FCF Yield for Evoke Pharma Inc (EVOK) as of Jan 09 2026?
As of Jan 09 2026, Evoke Pharma Inc (EVOK) has a FCF Yield of 0.00%. This means that for every dollar of Evoke Pharma Inc’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for Evoke Pharma Inc (EVOK) as of Jan 09 2026?
As of Jan 09 2026, Evoke Pharma Inc (EVOK) has a Forward P/E ratio of -4.72. This means the market is willing to pay $-4.72 for every dollar of Evoke Pharma Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Evoke Pharma Inc (EVOK) as of Jan 09 2026?
As of Jan 09 2026, Evoke Pharma Inc (EVOK) has a Forward P/S ratio of 0.50. This means the market is valuing EVOK at $0.50 for every dollar of expected revenue over the next 12 months.